These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 9323821

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of induction therapy on rejection and survival in heart transplantation.
    Almenar L, García-Palomar C, Martínez-Dolz L, Chamorro C, Moro J, Zorio E, Arnau MA, Rueda J, Osa A, Cardo ML.
    Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
    [Abstract] [Full Text] [Related]

  • 5. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M, Czer LS, Pan SH, Aleksic I, Freimark D, Harasty DA, Admon D, Barath P, Blanche C, Trento A.
    J Heart Lung Transplant; 1995 Nov; 14(4):659-65. PubMed ID: 7578172
    [Abstract] [Full Text] [Related]

  • 6. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
    Meiser BM, Uberfuhr P, Fuchs A, Schulze C, Nollert G, Mair H, Martin S, Pfeiffer M, Reichenspurner H, Kreuzer E, Reichart B.
    J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
    [Abstract] [Full Text] [Related]

  • 7. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, DeWitt CW, Jones KW, Gay WA, Menlove RL, Bristow MR.
    J Heart Lung Transplant; 1991 Aug; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [Abstract] [Full Text] [Related]

  • 8. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML, Sanchez JA, Seche LA, Schulman LL, Smith CR, Rose EA.
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [Abstract] [Full Text] [Related]

  • 9. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
    McNamara D, Di Salvo T, Mathier M, Keck S, Semigran M, Dec GW.
    J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
    Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson M, Heroux A, Kao W, Mullen GM, Radvany R, Robinson J.
    J Heart Lung Transplant; 1993 Aug; 12(5):779-89. PubMed ID: 8241215
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study.
    Ross HJ, Gullestad L, Pak J, Slauson S, Valantine HA, Hunt SA.
    J Heart Lung Transplant; 1997 Feb; 16(2):179-89. PubMed ID: 9059929
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
    Laske A, Gallino A, Schneider J, Bauer EP, Carrel T, Pasic M, von Segesser LK, Turina MI.
    J Heart Lung Transplant; 1992 Feb; 11(3 Pt 1):557-63. PubMed ID: 1610864
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prophylactic OKT3 used as induction therapy for heart transplantation.
    Starnes VA, Oyer PE, Stinson EB, Dein JR, Shumway NE.
    Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
    [Abstract] [Full Text] [Related]

  • 20. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG, O'Connell JB, Gilbert EM, Hammond ME, Burton NA, Jones KW, Karwande SV, Doty DB, Menlove RL, Herrick CM.
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.